Log in

NASDAQ:BVXV - BIONDVAX PHARMA/S Stock Price, Forecast & News

$10.25
+0.58 (+6.00 %)
(As of 01/19/2020 11:14 AM ET)
Today's Range
$9.50
Now: $10.25
$10.87
50-Day Range
$5.70
MA: $7.99
$11.13
52-Week Range
$4.65
Now: $10.25
$13.50
Volume45,508 shs
Average Volume58,865 shs
Market Capitalization$66.93 million
P/E RatioN/A
Dividend YieldN/A
Beta1.32
BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BVXV
CUSIPN/A
Phone972-8930-2529

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.27) per share

Profitability

Net Income$-23,410,000.00

Miscellaneous

Employees14
Market Cap$66.93 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive BVXV News and Ratings via Email

Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


A brand-new technology - code named "Halo-Fi" - could kill off your overpriced cable company for good... beaming lightning-fast internet to your home for an estimated $7 a month.

This is undoubtedly the beginning of the end for "Big 3" internet providers.

Forward-thinking investors in Halo-Fi are lining up to get rich before January 30th.

BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions

What is BIONDVAX PHARMA/S's stock symbol?

BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV."

How were BIONDVAX PHARMA/S's earnings last quarter?

BIONDVAX PHARMA/S (NASDAQ:BVXV) released its quarterly earnings data on Tuesday, November, 26th. The company reported ($0.57) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.03) by $0.54. View BIONDVAX PHARMA/S's Earnings History.

When is BIONDVAX PHARMA/S's next earnings date?

BIONDVAX PHARMA/S is scheduled to release their next quarterly earnings announcement on Tuesday, May 5th 2020. View Earnings Estimates for BIONDVAX PHARMA/S.

Has BIONDVAX PHARMA/S been receiving favorable news coverage?

Media headlines about BVXV stock have trended positive on Sunday, according to InfoTrie Sentiment. The research firm identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BIONDVAX PHARMA/S earned a coverage optimism score of 2.2 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for BIONDVAX PHARMA/S.

Are investors shorting BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S saw a increase in short interest during the month of December. As of December 31st, there was short interest totalling 29,700 shares, an increase of 364.1% from the December 15th total of 6,400 shares. Based on an average daily trading volume, of 18,800 shares, the short-interest ratio is currently 1.6 days. Approximately 0.5% of the company's stock are short sold. View BIONDVAX PHARMA/S's Current Options Chain.

Who are some of BIONDVAX PHARMA/S's key competitors?

What other stocks do shareholders of BIONDVAX PHARMA/S own?

Who are BIONDVAX PHARMA/S's key executives?

BIONDVAX PHARMA/S's management team includes the folowing people:
  • Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 57)
  • Mr. Uri Ben-Or CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 49)
  • Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 55)
  • Dr. Shimon Hassin, Chief Operating Officer
  • Mr. Elad Mark, Head of Site & Process Devel.

When did BIONDVAX PHARMA/S IPO?

(BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO.

How do I buy shares of BIONDVAX PHARMA/S?

Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BIONDVAX PHARMA/S's stock price today?

One share of BVXV stock can currently be purchased for approximately $10.25.

How big of a company is BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S has a market capitalization of $66.93 million. The company earns $-23,410,000.00 in net income (profit) each year or ($3.60) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe.View Additional Information About BIONDVAX PHARMA/S.

What is BIONDVAX PHARMA/S's official website?

The official website for BIONDVAX PHARMA/S is http://www.biondvax.com/.

How can I contact BIONDVAX PHARMA/S?

BIONDVAX PHARMA/S's mailing address is Jerusalem BioPark 2nd floor Hadassah Ein Kerem Campus, Jerusalem L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected]


MarketBeat Community Rating for BIONDVAX PHARMA/S (NASDAQ BVXV)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  158 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  338
MarketBeat's community ratings are surveys of what our community members think about BIONDVAX PHARMA/S and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel